Journal
THERANOSTICS
Volume 5, Issue 1, Pages 23-42Publisher
IVYSPRING INT PUBL
DOI: 10.7150/thno.10202
Keywords
aptamer; cancer therapy; active targeting; cancer stem cell; chemoresistance; cancer theranostic
Categories
Funding
- Australian Research Council [DP140100002]
- CASS Foundation
- Australia-India Strategic Research Fund
- Deakin University Postgraduate Research Scholarship
Ask authors/readers for more resources
Conventional anticancer therapies, such as chemo- and/or radio-therapy are often unable to completely eradicate cancers due to abnormal tumor microenvironment, as well as increased drug/radiation resistance. More effective therapeutic strategies for overcoming these obstacles are urgently in demand. Aptamers, as chemical antibodies that bind to targets with high affinity and specificity, are a promising new and novel agent for both cancer diagnostic and therapeutic applications. Aptamer-based cancer cell targeting facilitates the development of active targeting in which aptamer-mediated drug delivery could provide promising anticancer outcomes. This review is to update the current progress of aptamer-based cancer diagnosis and aptamer-mediated active targeting for cancer therapy in vivo, exploring the potential of this novel form of targeted cancer therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available